Should the emergence of new agents change the management of patients with acute coronary syndromes without ST-segment elevation?

American Heart Journal

Volumn 138, Issue 6 II, 1999, Pages

  Califf, R M ^a   Holmes D R , Jr ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; NEW DRUG; PLACEBO; TIROFIBAN;

ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CONSERVATIVE TREATMENT; CORONARY STENT; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; REBOUND; RESTENOSIS; ST SEGMENT ELEVATION; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0032732543     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1053/hj.1999.v138.a102300     Document Type: Conference Paper

References (29)

1. American Heart Association. 1998 Heart and Stroke Statistical Update. Dallas: American Heart Association; 1997.
2. TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Circulation 1994;89:1545-56.
3. VANQWISH Trial Investigators. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med 1998;338:1785-92.
4. Yusuf S, Flather M, Pogue J, et al. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. Lancet 1998;352:507-14.
5. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331:489-95.
6. Macaya C, Serruys PW, Ruygrok P, et al. Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. J Am Coll Cardiol 1996;27:255-61.
7. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
8. George CJ, Baim DS, Brinker JA, et al. One-year follow-up of the Stent Restenosis (STRESS I) study. Am J Cardiol 1998;81:860-5.
9. More RS, Chauhan A. Antiplatelet rather than anticoagulant therapy with coronary stenting. Lancet 1997;349:146-7.
10. Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-71.
11. FRagmin and Fast Revascularization During Instability in Coronary Artery Disease (FRISC-II) Investigators. Invasive compared with noninvasive treatment in unstable coronary-artery disease: FRISC-II prospective randomised multicentre study. Lancet 1999;354:708-15.
12. Madsen JK, Grande P, Saunamaki K, et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish Trial in Myocardial Infarction. Circulation 1997;96:748-55.
13. Coller BS. The role of platelets in arterial thrombosis and the rationale for blockade of platelet GP IIb/IIIa receptors as antithrombotic therapy. Eur Heart J 1995;16(suppl L):11-5.
14. The PRISM Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-505.
15. The PRISM-PLUS Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
16. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
17. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
18. Topol EJ, Califf RM, Weisman H, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343:881-90.
19. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
20. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
21. IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-8.
22. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
23. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics, and metabolism in humans. Haemostasis 1996;26(suppl 2):24-38.
24. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995; 26:313-8.
25. The FRISC study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-8.
26. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Circulation 1997;96:61-8.
27. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for coronary artery disease. N Engl J Med 1997;337:447-52.
28. Lablanche JM, McFadden EP, Meneveau N, et al. Effect of nadroparin, a low molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastie Coronarie Transluminale. Circulation 1997;96:3396-402.
29. The ERA Investigators. Low molecular weight heparin in prevention of restenosis after angioplasty. Circulation 1994;90:908-14.